SCHEMBL232440

SCHEMBL232440

CC(=O)NC(C(=O)O)C(C)O

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.45
CA2 P00918 4/20 0.42
CA1 P00915 3/20 0.42
SMN1; SMN2 Q16637 2/20 0.41
KDM4E B2RXH2 1/20 0.41
MAPT P10636 1/20 0.41
THRB P10828 1/20 0.41
ALOX15 P16050 1/20 0.41
NFKB1 P19838 1/20 0.41
PTGS2 P35354 1/20 0.41
THPO P40225 1/20 0.41
RECQL P46063 1/20 0.41
BLM P54132 1/20 0.41
TP53 P04637 1/20 0.41
MME P08473 2/20 0.40
PDCD1LG2 Q9BQ51 1/20 0.36
CD274 Q9NZQ7 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL232441 1.00 ALDH1A1 (0.45) ALDH1A1CA2CA1SMN1; SMN2KDM4E
SCHEMBL17439187 1.00 ALDH1A1 (0.45) ALDH1A1CA2CA1SMN1; SMN2KDM4E
SCHEMBL20951937 1.00 ALDH1A1 (0.45) ALDH1A1CA2CA1SMN1; SMN2KDM4E
SCHEMBL6026642 1.00 ALDH1A1 (0.45) ALDH1A1CA2CA1SMN1; SMN2KDM4E
SCHEMBL359087 1.00 ALDH1A1 (0.45) ALDH1A1CA2CA1SMN1; SMN2KDM4E
SCHEMBL23896338 1.00 ALDH1A1 (0.45) ALDH1A1CA2CA1SMN1; SMN2KDM4E
SCHEMBL6026636 1.00 ALDH1A1 (0.45) ALDH1A1CA2CA1SMN1; SMN2KDM4E
Benzene SCHEMBL3449157 0.95 MME (0.45) ALDH1A1CA2CA1SMN1; SMN2KDM4E
Glycine SCHEMBL20898378 0.88 ALDH1A1 (0.41) ALDH1A1CA2CA1SMN1; SMN2KDM4E
SCHEMBL30953203 0.88 MME (0.41) ALDH1A1CA2CA1SMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 594 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12584101-B2 Compositions and method of use for H5 competent Bifidobacterium longum subsp. Infantis INFINANT HEALTH, INC. (US) 2026-03-24 US claimed
US-20250388855-A1 COMPOSITIONS AND METHOD OF USE FOR H5 COMPETENT BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS Infinant Health, Inc (US) 2025-12-25 US claimed
EP-3555615-B9 MASS SPECTROMETRY ASSAY METHOD FOR DETECTION AND QUANTITATION OF KIDNEY FUNCTION METABOLITES METABOLON INC (US) 2025-03-19 EP claimed
EP-3555615-B1 MASS SPECTROMETRY ASSAY METHOD FOR DETECTION AND QUANTITATION OF KIDNEY FUNCTION METABOLITES METABOLON INC (US) 2024-10-30 EP claimed
US-12076432-B2 Method of repairing oxidatively treated hair CONOPCO, INC. (US) 2024-09-03 US claimed
US-20240271083-A1 COMPOSITIONS AND METHOD OF USE FOR H5 COMPETENT BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS INFINANT HEALTH, INC. (US) 2024-08-15 US claimed
CN-109563127-B Compounds, agents and uses thereof 麦特博隆股份有限公司 2024-01-05 CN claimed
US-11833127-B2 Compositions and methods for the treatment of fat infiltration in muscle AXCELLA HEALTH INC. (US) 2023-12-05 US claimed
CN-117147751-A Metabolic marker combination for assessing cardiovascular disease risk in a subject and uses thereof 深圳市绘云生物科技有限公司 2023-12-01 CN claimed
CN-110088615-B Mass spectrometry assay for detection and quantification of renal function metabolites 梅塔博隆股份有限公司 2023-08-22 CN claimed
US-20060063827-A1 Systemic administration of therapeutic amino acids and N-acetylamino acids YU RUEY J 2006-03-23 US claimed
EP-1570840-A2 TOPICAL COMPOSITION COMPRISING N-ACETYLALDOSAMINES OR N-ACETYLAMINO ACIDS Yu, Ruey J., Dr. (US) 2005-09-07 EP claimed
US-20050171194-A1 Enlargement of mucocutaneous or cutaneous organs and sites with topical compositions YU RUEY J (US) 2005-08-04 US claimed
WO-2005055947-A2 ENLARGEMENT OF MUCOCUTANEOUS OR CUTANEOUS ORGANS AND SITES WITH TOPICAL COMPOSITIONS YU RUEY J (US) 2005-06-23 WO claimed
US-6524593-B1 Alleviate or improve various cosmetic conditions and dermatological disorders, skin, hair, nails TRISTRATA, INC. 2003-02-25 US claimed
US-6159485-A COSMETICS; SKIN DISORDERS YUGENIC LIMITED PARTNERSHIP (US) 2000-12-12 US claimed
WO-2000040217-B1 TOPICAL COMPOSITION COMPRISING N-ACETYLALDOSAMINES OR N-ACETYLAMINO ACIDS YUGENIC LIMITED PARTNERSHIP (US) 2000-10-05 WO claimed
US-5519000-A OLIGOPEPTIDE CENTECOR, INC. (US) 1996-05-21 US claimed
WO-1995026744-A1 TUMOR NECROSIS FACTOR INHIBITORS CENTOCOR, INC. (US) 1995-10-12 WO claimed
US-5008372-A Reacting with anhydrous trifluoroacetic acid CORNELL RESEARCH FOUNDATION, INC. (US) 1991-04-16 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12584101-B2 Compositions and method of use for H5 competent Bifidobacterium longum subsp. Infantis FUT5, VNN1, FUT8 ALDH1A1 3094/4885CA2 3993/4885CA1 2740/4885
US-20250388855-A1 COMPOSITIONS AND METHOD OF USE FOR H5 COMPETENT BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS MRPL21, VNN1, NT5M ALDH1A1 3766/4885CA2 4792/4885CA1 4285/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.